Nantahala Capital Management - CUE BIOPHARMA INC ownership

CUE BIOPHARMA INC's ticker is CUE and the CUSIP is 22978P106. A total of 92 filers reported holding CUE BIOPHARMA INC in Q2 2021. The put-call ratio across all filers is 2.54 and the average weighting 0.2%.

Quarter-by-quarter ownership
Nantahala Capital Management ownership history of CUE BIOPHARMA INC
ValueSharesWeighting
Q3 2023$61,548
-37.0%
26,7600.0%0.01%
-44.4%
Q2 2023$97,674
-70.7%
26,760
-71.3%
0.01%
-65.4%
Q1 2023$333,070
+25.3%
93,2970.0%0.03%
+52.9%
Q4 2022$265,896
+27.8%
93,2970.0%0.02%
+30.8%
Q3 2022$208,000
-16.8%
93,297
-7.1%
0.01%0.0%
Q2 2022$250,000
-97.7%
100,464
-95.5%
0.01%
-97.3%
Q1 2022$10,952,000
-61.9%
2,244,359
-11.6%
0.48%
-52.0%
Q4 2021$28,724,000
-23.3%
2,539,700
-1.2%
1.01%
-14.4%
Q3 2021$37,461,000
+20.1%
2,571,082
-4.0%
1.18%
+33.3%
Q2 2021$31,195,000
-5.4%
2,677,666
-1.0%
0.89%
-8.1%
Q1 2021$32,989,000
+5.2%
2,703,983
+7.9%
0.96%
-0.8%
Q4 2020$31,360,000
-11.0%
2,506,772
+7.0%
0.97%
-9.8%
Q3 2020$35,250,000
-38.2%
2,342,216
+0.7%
1.08%
-37.3%
Q2 2020$56,995,000
+60.4%
2,325,388
-7.1%
1.72%
+29.2%
Q1 2020$35,529,000
+59.3%
2,503,840
+78.2%
1.33%
+93.7%
Q4 2019$22,303,000
+92.0%
1,404,941
+1.9%
0.69%
+59.4%
Q3 2019$11,618,000
-6.2%
1,378,1980.0%0.43%
+12.8%
Q2 2019$12,390,000
+82.5%
1,378,198
+57.0%
0.38%
+80.2%
Q1 2019$6,788,000
+64.5%
878,0980.0%0.21%
+66.9%
Q4 2018$4,127,000
-46.5%
878,098
+2.9%
0.13%
-38.9%
Q3 2018$7,721,000
+53.7%
853,098
+101.4%
0.21%
+2.5%
Q2 2018$5,024,000423,5800.20%
Other shareholders
CUE BIOPHARMA INC shareholders Q2 2021
NameSharesValueWeighting ↓
Bleichroeder LP 755,028$1,736,5640.43%
Monaco Asset Management SAM 359,739$827,4000.24%
Slate Path Capital LP 2,402,455$5,525,6470.15%
SANDERS MORRIS HARRIS LLC 346,212$713,4260.15%
ADVISORY RESEARCH INC 257,225$591,6180.08%
Robertson Stephens Wealth Management, LLC 478,500$1,100,5500.07%
Annandale Capital, LLC 65,000$1500.04%
Good Life Advisors, LLC 112,000$257,6000.03%
CARLSON CAPITAL L P 135,000$310,5000.02%
CORNERCAP INVESTMENT COUNSEL INC 57,888$133,1420.02%
View complete list of CUE BIOPHARMA INC shareholders